LIDEX
LOE ApproachingNDATOPICALSOLUTION
Approved
Apr 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LIDEX by Alvogen is clinical pharmacology: mechanism of action: lidexagel® 5% gel releases lidocaine from a mild acidic vehicle to stabilize the neuronal membrane by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby effecting local anesthetic action. First approved in 1984.
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIDEX is a topical solution small-molecule product approved in 1984 by Alvogen. The precise indication and mechanism of action are not specified in available data, but the topical route suggests dermatological or localized use. Patient population and therapeutic mechanism require additional product-specific documentation.
LOE Approaching
LOE approaching status signals potential team contraction and shift toward lifecycle management or generic transition support roles.
Mechanism of Action
CLINICAL PHARMACOLOGY: Mechanism of Action: LidexaGel® 5% Gel releases lidocaine from a mild acidic vehicle to stabilize the neuronal membrane by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby effecting local anesthetic action. A mild acidic vehicle lowers…
Worked on LIDEX at Alvogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.